Hannah Chang is a managing director at Wu Capital. She focuses on early-stage biopharmaceutical investments out of the firm’s San Francisco office which she leads. Representative investments include Semma Therapeutics (acquired by Vertex Pharmaceuticals), Akouos (Nasdaq: AKUS), PACT Pharma and Gemini Therapeutics.
She was previously an investment professional at 5AM Ventures where she helped found IDEAYA Biosciences (Nasdaq: IDYA) and served as a board observer for Crinetics Pharmaceuticals (Nasdaq: CRNX). Earlier in her career Dr. Chang was a project leader at Boston Consulting Group and a member of the Healthcare Practice.
Dr. Chang obtained her M.D. from Harvard Medical School, Ph.D. in Biophysics from Harvard University and B.A. in Chemistry from Princeton University. She trained clinically in internal medicine and ophthalmology at the Beth Israel Deaconess Medical Center and Massachusetts Eye and Ear Infirmary, respectively. She is a licensed physician in the District of Columbia.